Rock Springs Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $60M | Sell |
689,748
-5,262
| -0.8% | -$512K | 3.54% | 6 |
|
|
2025
Q4 | $74.4M | Sell |
695,010
-22,092
| -3% | -$2.34M | 3.81% | 6 |
|
|
2025
Q3 | $72.4M | Sell |
717,102
-144,051
| -17% | -$13.4M | 4.23% | 3 |
|
|
2025
Q2 | $54.4M | Buy |
861,153
+26,965
| +3% | +$1.65M | 3.39% | 4 |
|
|
2025
Q1 | $44.2M | Sell |
834,188
-328,530
| -28% | -$18.2M | 2.53% | 11 |
|
|
2024
Q4 | $65.1M | Sell |
1,162,718
-65,375
| -5% | -$3.61M | 2.48% | 10 |
|
|
2024
Q3 | $64.3M | Sell |
1,228,093
-52,400
| -4% | -$2.51M | 2.09% | 11 |
|
|
2024
Q2 | $52.6M | Sell |
1,280,493
-242,400
| -16% | -$9.68M | 1.58% | 21 |
|
|
2024
Q1 | $66M | Hold |
1,522,893
| – | – | 1.68% | 19 |
|
|
2023
Q4 | $70M | Sell |
1,522,893
-74,230
| -5% | -$2.34M | 1.72% | 20 |
|
|
2023
Q3 | $36.6M | Hold |
1,597,123
| – | – | 0.98% | 33 |
|
|
2023
Q2 | $26.3M | Hold |
1,597,123
| – | – | 0.63% | 52 |
|
|
2023
Q1 | $28.5M | Sell |
1,597,123
-163,742
| -9% | -$4.11M | 0.68% | 49 |
|
|
2022
Q4 | $51.3M | Hold |
1,760,865
| – | – | 1.23% | 30 |
|
|
2022
Q3 | $43.1M | Buy |
1,760,865
+357,567
| +25% | +$6.65M | 1.11% | 30 |
|
|
2022
Q2 | $5.82M | Buy |
1,403,298
+166,272
| +13% | +$910K | 0.17% | 94 |
|
|
2022
Q1 | $14.3M | Buy |
1,237,026
+609,846
| +97% | +$5.35M | 0.36% | 73 |
|
|
2021
Q4 | $6.26M | Buy |
627,180
+15,000
| +2% | +$169K | 0.14% | 112 |
|
|
2021
Q3 | $8M | Buy |
612,180
+5,900
| +1% | +$90.1K | 0.17% | 116 |
|
|
2021
Q2 | $11.9M | Buy |
606,280
+7,000
| +1% | +$145K | 0.23% | 104 |
|
|
2021
Q1 | $12.7M | Buy |
599,280
+108,941
| +22% | +$3.16M | 0.28% | 95 |
|
|
2020
Q4 | $14.6M | Buy |
490,339
+26,253
| +6% | +$667K | 0.31% | 93 |
|
|
2020
Q3 | $10.1M | Sell |
464,086
-48,025
| -9% | -$1.1M | 0.26% | 102 |
|
|
2020
Q2 | $11.4M | Buy |
512,111
+12,111
| +2% | +$236K | 0.31% | 97 |
|
|
2020
Q1 | $7.61M | Buy |
500,000
+155,000
| +45% | +$2.78M | 0.31% | 85 |
|
|
2019
Q4 | $7.92M | Buy |
345,000
+40,000
| +13% | +$889K | 0.25% | 92 |
|
|
2019
Q3 | $6.58M | Buy |
305,000
+70,000
| +30% | +$1.5M | 0.26% | 91 |
|
|
2019
Q2 | $5.17M | Buy |
235,000
+18,500
| +9% | +$467K | 0.19% | 101 |
|
|
2019
Q1 | $5.93M | Hold |
216,500
| – | – | 0.23% | 102 |
|
|
2018
Q4 | $5.82M | Buy |
216,500
+1,500
| +0.7% | +$41.5K | 0.27% | 92 |
|
|
2018
Q3 | $6.27M | Hold |
215,000
| – | – | 0.23% | 104 |
|
|
2018
Q2 | $6.72M | Buy |
215,000
+143,500
| +201% | +$3.92M | 0.26% | 107 |
|
|
2018
Q1 | $1.42M | Hold |
71,500
| – | – | 0.06% | 141 |
|
|
2017
Q4 | $2.08M | Buy |
+71,500
| New | +$1.89M | 0.09% | 130 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Rock Springs Capital Management's RYTM Position: Q1 2026 in Review
Rock Springs Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 0.76% in Q1 2026, selling an estimated $512K and leaving 689,748 shares worth $60M. The position accounts for 3.54% of the portfolio, ranked #6.
Rock Springs Capital Management first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $74.4M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Rock Springs Capital Management held 689,748 shares of Rhythm Pharmaceuticals worth $60M as of Q1 2026.
- Rock Springs Capital Management sold 5,262 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $512K.
- Rhythm Pharmaceuticals made up 3.54% of Rock Springs Capital Management's portfolio in Q1 2026, its #6 holding.
- Rock Springs Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Rock Springs Capital Management's Rhythm Pharmaceuticals position peaked at $74.4M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.